Trial Profile
An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Adalimumab
- Indications Anterior uveitis; Uveitis
- Focus Registrational; Therapeutic Use
- Acronyms JUVE-BRIGHT
- Sponsors Eli Lilly and Company
- 10 Apr 2023 Planned primary completion date changed from 10 Mar 2023 to 15 Jul 2023.
- 10 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2022 Planned End Date changed from 3 Dec 2027 to 21 Jul 2028.